Hemoglobin decline in cancer patients receiving chemotherapy without an erythropoiesis-stimulating agent
The aim of this study was to examine the rate and timing of hemoglobin decline from <10 g/dL to <9 g/dL in cancer patients receiving chemotherapy.
Pooled data from the placebo arms of six randomized, controlled trials (RCTs) of darbepoetin alfa and data from an aggregated US community oncology clinic electronic medical records (EMR) database were analyzed. Patients had baseline hemoglobin ≥10 g/dL (RCTs) or baseline hemoglobin between ≥10 g/dL and <11 g/dL (EMR episodes) that declined to <10 g/dL at least once during the study period. The proportion of patients/episodes with hemoglobin decline to <9 g/dL by 3, 6, and 9 weeks without erythropoiesis-stimulating agents was estimated from data in each of the data sources, as was the rate of transfusions in the RCTs.
Data from 411 patients receiving placebo in the RCTs and 10,523 patients (10,942 episodes) in the EMR database were analyzed. Forty percent and 35 % of RCT patients and EMR episodes, respectively, had a hemoglobin decline from <10 g/dL to <9 g/dL at week 3, 54 % and 43 % at week 6, and 58 % and 46 % at week 9. Of patients in the RCTs, 43 % required an RBC transfusion.
Hemoglobin can rapidly decline in cancer patients receiving chemotherapy with hemoglobin levels around 10 g/dL, particularly in patients ≥65 years of age. The rapid rate of hemoglobin decline in these patients should be considered for optimal anemia management.
- Knight K, Wade S, Balducci L (2004) Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 116(Suppl 7A):11S–26S CrossRef
- (2001–2011) Aranesp® (darbepoetin alfa) prescribing information v25. Amgen Inc., Thousand Oaks, CA, USA
- (2011) Procrit (epoetin alfa) prescribing information. Centocor Ortho Biotech Inc., Raritan, NJ, USA
- European Medicines Agency. European public assessment reports for authorised medicinal products for human use. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000332/human_med_000651.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124&jsenabled=true. Accessed 7 February 2012
- Elliott S, Pham E, Macdougall IC (2008) Erythropoietins: a common mechanism of action. Exp Hematol 36:1573–1584 CrossRef
- Canon JL, Vansteenkiste J, Hedenus M, Gascon P, Bokemeyer C, Ludwig H, Vermorken J, Legg J, Pujol B, Bridges K (2011) Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus >/=10 g/dL: an exploratory analysis of a phase 3 trial. Med Oncol. doi:10.1007/s12032-12011-10103-x
- Eisterer W, Hussl C, Erb H, Haslbauer F, Sormann S, Braun S, Jaeger C (2011) RETRA: evaluating the transfusion rate with darbepoetin alfa 500 μg every 3 weeks in anaemic cancer patients receiving chemotherapy. Curr Med Res Opin 27:355–363 CrossRef
- Feinberg B, Gilmore J, Gondesen T, Jackson JH, Saleh M (2009) Impact of NCD guidelines on Medicare patients with chemotherapy-induced anemia receiving erythropoiesis-stimulating agents: results from a community oncology practice. Community Oncol 6:257–261 CrossRef
- Kotasek D, Steger G, Faught W, Underhill C, Poulsen E, Colowick AB, Rossi G, Mackey J (2003) Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 39:2026–2034 CrossRef
- Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, Siena S, Gateley J, Tomita D, Colowick AB, Musil J (2002) Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94:1211–1220 CrossRef
- Pirker R, Ramlau RA, Schuette W, Zatloukal P, Ferreira I, Lillie T, Vansteenkiste JF (2008) Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. J Clin Oncol 26:2342–2349 CrossRef
- Hedenus M, Hansen S, Taylor K, Arthur C, Emmerich B, Dewey C, Watson D, Rossi G, Osterborg A (2002) Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol 119:79–86 CrossRef
- Hedenus M, Adriansson M, San Miguel J, Kramer MH, Schipperus MR, Juvonen E, Taylor K, Belch A, Altes A, Martinelli G, Watson D, Matcham J, Rossi G, Littlewood TJ (2003) Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 122:394–403 CrossRef
- Hernandez E, Ganly P, Charu V, Dibenedetto J, Tomita D, Lillie T, Taylor K (2009) Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia. Curr Med Res Opin 25:2109–2120 CrossRef
- Wu Y, Aravind S, Ranganathan G, Martin A, Nalysnyk L (2009) Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000–2007. Clin Ther 31(Pt 2):2416–2432 CrossRef
- den Elzen WP, Gussekloo J (2011) Anaemia in older persons. Neth J Med 69:260–267
- Vincent M, Dranitsaris G, Verma S, Lau C, Gascon P, Van Belle S, Ludwig H (2007) The development and validation of a prediction tool for chemotherapy-induced anemia in patients with advanced nonsmall cell lung cancer receiving palliative chemotherapy. Support Care Cancer 15:265–272 CrossRef
- Hemoglobin decline in cancer patients receiving chemotherapy without an erythropoiesis-stimulating agent
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Supportive Care in Cancer
Volume 21, Issue 4 , pp 987-992
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Medical University Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria
- 5. Department of Medicine I, Medical University Vienna, Vienna, Austria
- 2. SDI Health, One IMS Drive, Plymouth Meeting, PA, 19462, USA
- 3. Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91320, USA
- 4. University Hospital Gasthuisberg, Herestraat 49, 3000, Leuven, Belgium